ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Engineering Bacteria as Living Therapeutics in Cancer Therapy.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- Synthetic biology of oncolytic bacteria: Comparative microbial chassis and precise killing strategies.Toxicology reports · 2026Review
- Surface display of co-stimulatory ligand B7H2 on engineered bacteria enhances tumor immunotherapy.Cell reports. Medicine · 2026Article
- Spatial Heterogeneity of Intratumoral Microbiota and Its Roles in Tumor-Microbiota Interactions and Therapeutic Implications.Pathogens (Basel, Switzerland) · 2026Review
- A microwave-programmable abiotic/biotic hybrid system for integrated tumor eradication, immune activation, and bone regeneration.Materials today. Bio · 2026Article
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Engineered Bacteria-Vesicle Delivered Lactate Reprogramming Boosts Tumor Radiosensitivity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineering Bacteria as Living Therapeutics in Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the second-leading cause of death globally, yet traditional therapies like chemotherapy face significant limitations. Recent advances in synthetic biology enable the design of various genetic circuits and the reprogramming of biological systems. Collectively, these efforts have led to the repurposing of engineered bacteria as therapeutics to achieve tumor targeting, tumor microenvironment modulation, and anticancer drug release. Here, these recent efforts are reviewed and discussed the challenges and future opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.